United Therapeutics Corporation drugs
5 results
Adcirca (tadalafil)
(Tadalafil)United Therapeutics Corporation
Usage: ADCIRCA® is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability, primarily in patients with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH associated with connective tissue diseases.
Orenitram (treprostinil)
(treprostinil)United Therapeutics Corporation
Usage: Orenitram is indicated for treating pulmonary arterial hypertension (PAH) to delay disease progression and improve exercise capacity, particularly in patients with WHO functional class II-III symptoms, including idiopathic, heritable PAH, and PAH associated with connective tissue disease.
Remodulin (treprostinil)
(treprostinil)United Therapeutics Corporation
Usage: Remodulin is indicated for treating pulmonary arterial hypertension (PAH; WHO Group 1) to reduce exercise-related symptoms. It is also indicated for patients transitioning from epoprostenol to decrease clinical deterioration, considering the associated risks and benefits.
Tyvaso (treprostinil)
(treprostinil)United Therapeutics Corporation
Usage: Tyvaso is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability in patients with NYHA Functional Class III symptoms and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its effectiveness is mainly in patients with specific underlying conditions like idiopathic pulmonary fibrosis and connective tissue diseases.
Unituxin (dinutuximab)
(DINUTUXIMAB)United Therapeutics Corporation
Usage: Unituxin (dinutuximab) is indicated for use, alongside GM-CSF, IL-2, and 13-cis-retinoic acid, in pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.